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 10 
Introduction  11 
Lexchin (1998) has described appropriate prescribing as ‘trying to maximise effectiveness, minimise 12 
risks and costs, and respecting service users’ choices (1). Of importance in judging prescribing 13 
appropriateness are what the service users wants or prefers as well as the scientific rationalisation (2, 14 
3). 15 
 16 
Among people with substance misuse problems, their wider physical, psychological and social 17 
outcomes as well as their views may be particularly important when assessing the appropriateness of 18 
their medications. People with substance misuse problems often have complex circumstances 19 
encompassing health, social and economic problems (4, 5), with service users attending specialist 20 
addiction clinics being more likely to have higher levels of dependence, multi-morbidities, functional 21 
impairment, social problems and use of multiple medications when compared with those who are not 22 
help-seeking (6, 7). These complex needs may influence prescribing decisions in this population (7, 8). 23 
For example, people with co-existing substance misuse problems and mental disorders may need higher 24 
doses or longer duration of treatment because they may have more severe and persistent symptoms or 25 
they may be more resistant to treatment (9, 10).  26 
 27 
Most of the published research on prescribing appropriateness has focused on the assessment of 28 
pharmacological appropriateness (3). Examples of measures used for assessing this include the 29 
medication appropriateness index (MAI) (11) and the prescribing appropriateness index (PAI) (12). 30 
Moving beyond the medical perspective by considering service users’ preferences and context, 31 
introduces subjectivity into decision-making concerning appropriateness. Barber et al. (2005) have 32 
argued that the introduction of subjectivity is appropriate when making value judgments such as this. 33 
 34 
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Furthermore, given that intoxication and withdrawal symptoms of substances often mimic those of 35 
anxiety and mood disorders, an important clinical question relates to whether and when psychotropic 36 
medications could be used in treating the mental health symptoms of people with substance misuse 37 
problems (13-15). There is inconsistent evidence that psychotropic medications such as antidepressants 38 
and sedative/hypnotic drugs have beneficial effects on co-existing mental disorders in this population 39 
(16-19). 40 
  41 
It has been suggested that the service user’s perspective is particularly important and should be 42 
considered where there is a lack of adequate evidence or doubt about the best course of action (20, 21). 43 
In the UK, the NHS constitution states that the service it provides must reflect the needs and preferences 44 
of service users (22). Partnership with service users with open communication and consideration of 45 
their values and choices have been promoted in UK government policies and clinical guidance (23, 24), 46 
with positive effects reported on satisfaction, medication adherence and well-being. Additional benefits 47 
described among those with substance misuse problems include increased personal control and reduced 48 
drug use (25, 26). Generally, service users want to be involved in decision-making concerning their 49 
treatment and medications (26). However, they often report feeling uninvolved in decision-making (27). 50 
A qualitative study that explored the experiences of service users in treatment for alcohol use disorders 51 
around their treatment needs and satisfaction while also comparing the experiences of those with and 52 
without co-morbid severe mental health symptoms (SMHS) found that those with comorbidity 53 
described a need for medications to relieve their psychological symptoms and were often dissatisfied 54 
when they were left out in the decision making process (including prescribing) (27). Although this study 55 
described the treatment needs of service users with comorbid SMHS, it was not focused on the 56 
appropriateness of prescribed psychotropic medications. No previous study has explored the views of 57 
people attending an addiction service concerning the appropriateness of psychotropic medications 58 
prescribed for their co-occurring mental illness. Consequently, this study was carried out to address this 59 
gap. Diagnoses of mental health illnesses and psychotropic medications were self-reported by service 60 
users. 61 
This study was part of the first author’s (A.O) PhD programme. As a pharmacist, A.O has always had 62 
an interest in the quality of prescribing for service users, including those with substance misuse 63 
problems. A.O’s pharmacy training with emphasis on the use of medications for the management of 64 
substance misuse problems made her initially more inclined to view these disorders as brain diseases. 65 
Hence, A.O came with a medical perspective of substance misuse problems when she started her 66 
doctorate programme. 67 
 68 
 69 
 70 
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Aim 71 
To explore the perspectives of service users in a specialist addiction service on the appropriateness of 72 
psychotropic medications prescribed for their co-existing mental health problems. Appropriateness was 73 
explored by assessing service users’ views concerning the following areas: their need for medications, 74 
medication effectiveness, medication changes, assessment and review.  75 
 76 
Ethics approval 77 
The study was approved by the University of York’s Research Governance Committee and the National 78 
Research Ethics Service (NRES) Committee Yorkshire & The Humber. Reference 12/YH/0325. 79 
 80 
Methods 81 
Study design and setting  82 
Service users’ views were explored using a phenomenological approach. Phenomenology is based on 83 
the assumption that reality is multiple and socially constructed through the interaction of individuals 84 
with others and the world around them (28). Semi-structured qualitative interviews were carried out 85 
with 14 service users who were attending the specialist addiction service. The specialist addiction 86 
service has been described in a previous study (7). Briefly, it is located in a city in the North of England 87 
and is a statutory NHS specialist service that provides a full range of psychosocial and 88 
pharmacotherapies for addiction problems. All interviews were carried out at service users’ three-month 89 
follow-up appointment or at their next appointment if this was more convenient. Interviews were carried 90 
out with a single service user at a time due to the sensitivity of the topic and to maintain confidentiality 91 
(29).      92 
 93 
Participants 94 
Interviews were carried out with a convenience sample of 14 service users on current prescriptions of 95 
psychotropic medications. Of these 14, two service users provided very limited information and their 96 
data were not presented. Only data from 12 service users were reported. Psychotropic medications 97 
included in this study were antidepressants, anxiolytics/hypnotics, anticonvulsants, antipsychotics and 98 
mood stabilisers. All service users who were interviewed also took part in an earlier study (30) in 99 
which the appropriateness of opioids and psychotropic medications were assessed using a modified 100 
form of the Medication Appropriateness Index (11). Convenience sampling involves recruiting people 101 
who are available to take part in research (31), and may not be representative of the study population 102 
(32). Service users who were still attending the specialist addiction service prior to their three-month 103 
follow-up appointment and who were on prescribed opioids and/or psychotropic medications at their 104 
first assessment were contacted by telephone to determine if they could be interviewed during their 105 
follow-up appointment. Twenty three service users were on these prescribed medications and 20 of 106 
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them were contacted by telephone to determine if they would consent to participate in an interview 107 
during their follow-up assessment. The remaining three service users could not be contacted. Four 108 
service users were not interviewed because they did not attend for their scheduled interviews while 109 
two service users attended but declined interview. Therefore, a total of 14 service users (of 20: 70%) 110 
were interviewed and data from 12 of them are presented (60%).  111 
 112 
Service users who provided consent and attended the service for their follow-up appointment were 113 
reminded of the study aims and encouraged to ask for clarification where needed. They were then given 114 
a consent form to sign before the interviews commenced. The service users who were interviewed 115 
comprised two females and 10 males. Alcohol was the referral substance for all but two service users 116 
who were referred for problems with heroin. The mean age of those interviewed was 48.6 years (range: 117 
26 to 66 years) and the number of psychotropic medications they were being prescribed at their three-118 
month assessment ranged from 1 – 4.   119 
 120 
Data collection 121 
Data were collected by the first author, A.O. All the interviews were conducted in a private room at the 122 
specialist addiction service between October 2012 and April 2013 and lasted on average 47 mins (range: 123 
15 to 104 mins). The topic guide for service users was developed from the research questions and advice 124 
from the project advisory group. It covered the following areas: service users’ medical/substance use 125 
history, need for medications, effectiveness of medications, assessment and review, medication change 126 
and quality of life. The views of ex-service users who serve as mentors for other service users at the 127 
specialist addiction service were sought about the topic guide. All interviews were audio-recorded and 128 
transcribed verbatim.  129 
 130 
Data analysis 131 
Thematic framework approach was used for data analysis (33). Repeated reading of the transcripts 132 
alongside listening to the audio-recordings ensured that the authors were familiar with the data. This 133 
was followed by a period of descriptive and interpretive coding facilitated by Atlas ti (v 6.0). This 134 
inductive approach enabled a deeper understanding of the data (33). The coding framework was 135 
expanded as new themes emerged. Broader themes were subsequently generated and frequently 136 
reviewed while comparing data from participants that supported the themes and also looking for 137 
explanations of any differences of viewpoints within the data. In order to ensure anonymity and 138 
confidentiality, numbers rather than names were allocated to participants. Trustworthiness of the data 139 
was ensured through an audit trail kept by A.O which detailed how data were collected, how themes 140 
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were formed and how decisions were made during the research process. Given A.O’s initial views on 141 
substance misuse problems as brain diseases, the interpretation of the data was discussed in-depth with 142 
two of the authors (C.L and E.H), who reflected on the emerging themes and the depth of the analysis. 143 
C. L and E.H studied criminology and nursing respectively. D.R is a consultant addictions psychiatrist.  144 
 145 
Results 146 
Three main themes emerged by undertaking a thematic analysis: benefits of medicines, entitlement to 147 
medicines, and assessment and review. Two subthemes, medication review and discussion with 148 
clinicians, are further described under assessment and review. 149 
 150 
Benefits of medicines 151 
This theme emerged in response to service users’ views concerning the need for their medicines and 152 
effectiveness. All service users described their medicines in relation to the effect they had on their health 153 
conditions and wider life. Most service users thought that their medicines had led to some degree of improvement 154 
in their health conditions and functioning. Below is a description of the positive impact of antidepressants on a 155 
service user’s functioning: 156 
…because a few months ago, I didn’t take them [Citalopram] for a while and I just hit rock bottom 157 
again and then when I started back on them again, within a couple of weeks I was back to normal [ID 158 
5, male, heroin dependency]. 159 
As well as the health impact of their medicines, service users also described their medicines (in 160 
particular, antidepressants) as providing valuable support in their lives: 161 
…and during a very stressful period which, my mood didn’t really change that much, I used it as like a 162 
comfort blanket or a crutch to sort of like, I’m taking 40mg [Citalopram] now, so I’m bound to be all 163 
right [ID 23, male, alcohol dependency]. 164 
Among service users who described positive effects from their medicines were those who reported benefits 165 
despite being prescribed outside the British National Formulary (BNF) recommendations. One elderly service 166 
user referred for his alcohol problems, with a 12-year history of olanzapine use at a dose above the BNF 167 
recommendation for long-standing paranoid schizophrenia, described the benefit he derived from his medicine: 168 
As soon as I was put on 25mg of Olanzapine a day, at night, all slight psychotic symptoms disappeared. 169 
And I’ve been on those tablets for a number of years now and I find that they do very well for me 170 
6 
 
psychiatrically. I haven’t been mentally ill for something like oh about ten/twelve years now… thanks 171 
to the medications [ID18, male, alcohol dependency]. 172 
There was also an awareness that alcohol could have a negative impact on the effectiveness of their 173 
antidepressants. The service user with long-standing paranoid schizophrenia described above recounted 174 
periods of depression despite being on fluoxetine and mirtazapine. He attributed this to continued 175 
drinking. 176 
Another service user with a year history of zopiclone use for sleep problems described benefit from his 177 
zopiclone (the duration of zopiclone use had exceeded BNF recommendations): 178 
The Zopiclone works because within ten, twenty minutes I’m asleep. So that does work [ID 15, male, 179 
alcohol dependency]. 180 
Service users further described having side effects which they tolerated due to the benefits they felt they 181 
obtained. One service user with a five-year history of citalopram use for long-standing depression 182 
described sexual dysfunction resulting from citalopram but reported that it was nevertheless effective 183 
for his depression: 184 
 185 
Citalopram’s been great. Easy to work with, you know, easy to take, it doesn’t make me drowsy. I can 186 
live a normal life on it, and I’m happy now. The only contraindication or side-effect I have from 187 
citalopram is that sometimes it prevents ejaculation. I can get to the point of climax but, I don’t ejaculate 188 
[ID 23, male, alcohol dependency]. 189 
Almost all service users who had changes made to their medicines described improved functioning as 190 
a result of this.  191 
 192 
Entitlement to medicines 193 
While describing the need for their medicines and its effectiveness, service users went ahead to describe a sense 194 
of entitlement to being prescribed medicines: 195 
Well my personal opinion is that I think with doctors these days, I think you have to tell them what’s 196 
wrong with you or basically tell ‘em what you need, rather than the sort of old school where you went 197 
to the doctor and you spent a long time explaining your symptoms (ID 7, male, alcohol dependency). 198 
I do appreciate that they [Zopiclone] are addictive but so’s smoking, so’s driving really fast, so’s doing 199 
a lot of other things. It’s my health and I’ve chosen to look after it how I want and this is how I want 200 
(ID 57, male, alcohol dependency). 201 
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This theme was also evident when another service user who had deliberately taken an overdose of his 202 
prescribed antidepressant (fluoxetine) and sleeping tablet (zopiclone) in order to self-harm and had been 203 
admitted to hospital was afraid his zopiclone could be stopped by his GP but demonstrated a recognition 204 
of his right to be prescribed it: 205 
And the sleeper [Zopiclone], they (hospital doctors) won’t prescribe it to me, so now I have to go back 206 
to my GP and hope that he’ll prescribe me it again, because obvious he’s gonna know on computer that 207 
I took an overdose, so he might refuse me  treatment so I’ve put meself in a predicament there to try 208 
and get me medication back but I know he can’t refuse it because he’s putting me physically in danger 209 
then (ID 27, male, alcohol dependency).  210 
 211 
Assessment and review 212 
Two subthemes were described under this category: medication review and discussion with clinicians. 213 
 214 
Medication review 215 
This theme came out when service users were asked about the assessment and review of their medicines 216 
with most service users describing regular review of their medicines: 217 
Yeah, I have reviews every, I think it’s every couple of months or every few months, to see if I’m still ok 218 
on the medication, so the GP knows that it’s working basically. I get reviews ever so often. So they can 219 
know that it’s doing what it’s supposed to be doing [ID 61, female, alcohol dependency]. 220 
It [Paroxetine] has been reviewed several times and, he said “I don’t want you to come off it just yet.” 221 
and it’s due to be reviewed, so he’s [GP] going to see me and review it [ID 15, male, alcohol 222 
dependency].  223 
By contrast, there were service users who described lack of optimal practices regarding review of their 224 
medicines:  225 
But what happens with GPs and practices, you just become a repeat prescription, and I can go for a 226 
year without a review when they’re supposed to be every two months or every three, you know, you can 227 
be left to sort of float around. And I can ring the chemist up and say “I need another script”. And he’ll 228 
go “right, OK” and it’s there two days later. You don’t have to go see a GP. But that’s always been the 229 
case, which is not really about monitoring the effect of the drug, it’s more a case of, well you’re on it 230 
now, so just keep taking it [ID 23, male, alcohol dependency]. 231 
 232 
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Discussion with clinicians 233 
Service users described discussion with clinicians as important in assessing if their medicines are ‘right’ 234 
for them. They described the value of talking and listening to them: 235 
Talking to me, listening to me, asking me, you know, why I was feeling the way I was, was there anything 236 
that had triggered things off, that sort of thing [ID 35, female, alcohol dependency]. 237 
Another service user with a particularly strong sense of entitlement to his medication (zopiclone) 238 
described how this process provided an opportunity for him to express his views on what he wants: 239 
Oh sitting down, talking to him about sleeping tablets and what I want, it’s up to me really [ID 57, 240 
male, alcohol dependency]. 241 
On the other hand, there were service users who described not being listened as well as the short interval 242 
in which he was prescribed a medication:  243 
… I could do with something better for my anxiety but I don’t know what other medication I can get. 244 
I’m just taking what the doctor prescribed me. I feel like I could, it would be nice if they could give me 245 
something to help me relax more [mentions Temazepam later], you know what I mean, to calm me down 246 
but the doctor won’t prescribe anything for me like that [ID 5, male, heroin dependency]. 247 
… So I was just telling the doctor basically what my problems were and was prescribed Paroxetine, 248 
yeah, Paroxetine, I don’t think my GP probably listened and, yeah, listened and prescribed me a drug. 249 
I just went for a five minute chat with my doctor … it was just I went for a quick meeting with my GP 250 
and told him my problems and sent away with a prescription [Paroxetine] It was just, go to the doctor 251 
and off you go, there’s your prescription off you go [ID 7, male, alcohol dependency]. 252 
 253 
Discussion 254 
This qualitative study aimed to explore service users’ views on the appropriateness of psychotropic 255 
medications prescribed for their co-existing mental health problems. Generally, service users described 256 
benefits from their medications (including those prescribed outside guideline recommendations) with 257 
trade-offs between their benefits and adverse effects. Service users had a sense of entitlement to being 258 
prescribed medications and seek to direct treatment decisions in line with their self-perceived needs. 259 
There were differing practices regarding the assessment and review of their medications.  260 
 261 
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Most service users described benefits from their medications, including service users who had been 262 
prescribed medications outside guideline recommendations. It was unclear whether all those prescribed 263 
outside guideline recommendations were aware of it because the interviews did not explore this issue 264 
due to its sensitive nature. Prescribing outside guideline recommendations (off-label prescribing) is 265 
common in psychiatry (34) due to the limited number of clinical trials on patients with mental health 266 
problems (especially those with complex needs) (35) as well as the non-availability of licensed 267 
medications for some psychiatric diagnoses (36). Off-label prescribing may therefore be necessary 268 
where there is a lack of an equally safe and effective licensed alternative, informed consent from the 269 
patient to be treated off-label, sufficient evidence in the literature to support the use of the drug as well 270 
as sufficient experience of using the medicine by the prescriber (36).  271 
 272 
Best practice recommendations including dosing and duration recommendations are usually established 273 
in clinical trials especially RCTs and where available, they serve as the foundation for clinical 274 
guidelines (37, 38) including the BNF. Where there is no evidence from clinical trials, recommendations 275 
are based to a large extent on the opinions of experts who have substantial experience in that area (39). 276 
It may not be possible to directly extrapolate recommendations from guidelines on prescribing of 277 
psychotropic medications to people with substance misuse problems because most of the evidence from 278 
RCTs exclude them (40, 41). Changes in the neurochemistry of the reward pathways of the brain 279 
secondary to chronic use of substances may also affect prescribing decisions (42) including dosing. 280 
Furthermore, consideration of the repercussions of relapse to substance use on the individual and society 281 
may well justify the need to sometimes prescribe outside guideline recommendations. Evidence from 282 
this study suggests that the appropriateness of prescribing is open to interpretation as some service users 283 
tended to view medications that improved their functioning as appropriate for them even when they 284 
were inappropriate by guideline standards.  285 
 286 
While off-label prescribing may be clinically beneficial (34) for people with substance misuse 287 
problems, it also carries clinical risks such as adverse effects. For instance, prescribing supra-BNF doses 288 
of antipsychotics carries a greater risk of unwanted side effects such as extrapyramidal side effects, 289 
sedation, tachycardia, weight gain, postural hypotension, and hyperprolactinaemia (43). The need for 290 
high doses of psychotropic medications such as anxiolytics/hypnotics may also expose the patient to 291 
the risk of dependence. In addition, people with substance misuse problems may exceed the 292 
recommended doses of these medications with the potential for overdosing (44). Although prescribers 293 
to achieve clinical benefit with minimal risk of harm, there is sometimes conflict between balancing 294 
effectiveness and risk (45).  295 
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 296 
Service user involvement in their own care now represents a core value in the medical profession and 297 
UK National Health Service (NHS) (24, 46). The NHS constitution states that NHS services must reflect 298 
the needs and preferences of service users (22). However, there is sometimes conflict between 299 
physician-assessed need and what service users want, and how far prescribing should be determined by 300 
either of this remains an unresolved question (2, 45). Service users often have complex needs and risk 301 
issues that need to be taken into consideration in treatment decisions. Service users’ choices are 302 
challenging when people have substance misuse problems because they may be less than open about 303 
the reasons why they want medications. Given that service users may be at risk from medications (13, 304 
44, 47), prescribing decisions should be justified, and also be with due precautions that may involve 305 
limit setting, monitoring and behavioural rules in this population (44). Nevertheless, prescribers may 306 
be under considerably greater pressure to respond to the self-perceived needs of substance users 307 
compared with other patient groups. People with substance misuse problems appear to have a 308 
particularly strong sense of their own needs and seek to make their own choices about their 309 
prescriptions. This sense of empowerment may well influence prescribing decisions.  310 
 Furthermore, there should be effective communication between the prescriber and service user for the 311 
best decision to be arrived at (48, 49). The responses of service users in this study highlighted the fact 312 
that many of them valued this two-way communication. However, there were service users who 313 
described ineffective communication or dissatisfaction with their medications. This finding supports 314 
the results of a previous study (27) where service users with co-existing severe mental health symptoms 315 
and alcohol use disorders valued being involved in treatment decisions and expressed the need for 316 
control over them. Service users in this previous study were often dissatisfied when decisions were 317 
made without their input. Service users usually report better satisfaction, medication adherence, 318 
improved well-being, increased personal control and reduction in drug use when clinicians partner with 319 
them in decision-making (25, 26). Health care strategies and UK guidance have also highlighted the 320 
importance of partnering with service users (23, 24).  321 
It has been suggested that prescribing may be used as a means of terminating difficult consultations 322 
(50). This may be more common in those with substance misuse problems, especially in time-pressured 323 
settings such as general practice (51). This suggests that where service users with substance misuse 324 
problems do have their health conditions reviewed, GPs may prescribe without careful assessment and 325 
prescriptions may therefore be inappropriate.  326 
 327 
There is a growing trend to use mood-altering drugs including antidepressants to treat instances of 328 
human distress or emotional unhappiness (52, 53). It is possible that prescribing in response to life’s 329 
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challenges and problems may be more common among people with substance misuse problems because 330 
of their high levels of vulnerability. Their situations are often complex with family disruptions, social 331 
and economic deprivation being prominent features (5, 54). The lifestyle of service users usually 332 
contributes to these problems and may result in demoralisation, a sense of distress and hopelessness 333 
(44) which prescribers may be tempted to ‘fix’ with a pill. It is noteworthy that although medications 334 
are often very accessible they may not be the optimal solution. There is therefore the need for 335 
practitioners who are competent in delivering appropriate psychosocial therapies as protracted 336 
prescribing should be secondary to interventions geared to motivating people to make significant 337 
lifestyle changes. Integrated treatment by multidisciplinary teams with a focus on both the mental health 338 
disorder and substance misuse problem using a combination of pharmacotherapy and psychotherapy 339 
may also be needed. This approach has been shown to be more effective for the management of this 340 
comorbidity (55, 56).   341 
Repeat dispensing services, where repeat supply of medications are managed by the service user’s 342 
pharmacy of choice, was introduced in the NHS community pharmacy contractual framework in 2005 343 
in order to manage repeat prescriptions more efficiently (57). Pharmacies are required to have 344 
appropriate governance in place for this service (58). Service users who are suitable for repeat 345 
dispensing include those with stable therapy, long-term conditions, multiple therapies and those who 346 
can self-manage seasonal conditions (57). This list is not exhaustive as other patient categories could 347 
be added based on clinical assessment. Repeat dispensing requires consent from the service user for 348 
their information to be shared between the dispensing and prescribing site. Recent evidence has 349 
shown that service users and prescribers value repeat prescribing and dispensing as it has the 350 
advantage of saving time, is convenient and also flexible (59, 60). Repeat prescribing further reduces 351 
the workload of prescribers. However, there have also been concerns around repeat dispensing in 352 
primary care with majority of respondents in the report by Petty (2017) stating that pharmacists never 353 
checked the items that were needed when they were ordered on behalf of the service users. The views 354 
expressed by some service users in this study clearly suggest that repeat prescribing and dispensing 355 
were not being regularly reviewed. Without on regular review of repeat medications, service users 356 
may end up being stuck on unnecessary medications and may become dependent medications that 357 
have such tendencies. Furthermore, it is also impossible to evaluate whether service users are still 358 
taking their medications with repeat prescribing. Consequently, lack of regular review of repeat 359 
prescriptions can lead to failure to detect and resolve drug-therapy problems as well as drug wastage 360 
(61).  361 
 362 
Over the course of this study and her doctorate programme, A.O’s engagement with service users, 363 
clinicians and the literature has broadened her views on substance misuse problems. She now considers 364 
substance misuse problems to be complex disorders involving social, psychological and behavioural 365 
mechanisms.  366 
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Strengths and limitations 367 
To the knowledge of the authors, this is the first study to explore the views of service users attending a 368 
specialist addiction service on the appropriateness of psychotropic medications prescribed for their co-369 
occurring mental health problems. Given that service users with substance misuse problems are difficult 370 
to recruit into research studies, a convenience sample of service users were interviewed. Consequently, 371 
the views of females and those with referral substances other than alcohol were under-represented in 372 
the interviews. Another limitation of this study is the fact that diagnoses and psychotropic medications 373 
were self-reported. There was no independent assessment of service users’ diagnoses. Most service 374 
users who took part in this study were referred from sources other than GPs to the addiction service and 375 
GP/referral notes were not available. Consequently, self-report was used as the source of information 376 
about diagnoses and prescribed medications. The findings may lack transferability to service users in 377 
other addiction services, especially given the changes that have occurred in substance misuse services 378 
in the UK. There has been an increase in the number of non-statutory and private sector providers of 379 
drug and alcohol services. Future research should involve multiple sites (including services run by the 380 
NHS and third sector organisations), to establish if the findings of this study are applicable. 381 
Furthermore, a single researcher collected study data and the researcher’s own perspectives may have 382 
affected interpretations that were made. However, the conduct, analysis and interpretation of data were 383 
overseen by two of the authors. 384 
 385 
Conclusion 386 
Service users’ views concerning the appropriateness of their prescribed psychotropic medications were 387 
varied with most service users describing improved functioning as a result of their medications 388 
(including off-label prescribing). It is clear that prescribing practices around substance misuse problems 389 
and comorbidities frequently deviates from current guidelines and it is unlikely that any guideline 390 
committee would sanction the sort of pharmacotherapy. This study suggests that some prescriptions are 391 
inappropriate in terms of their usual indications but if they can be used to maintain equilibrium in service 392 
users’ lives while moving them on to recovery then such prescribing might be justified. Finally, this 393 
study points to the need for ready availability of practitioners who are competent in delivering 394 
appropriate psychosocial therapies to motivate people to making significant lifestyle changes especially 395 
in the face of protracted prescribing.  396 
 397 
 398 
 399 
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